Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Follow-Up Questions
Who is the CEO of Passage Bio Inc?
Mr. William Chou is the President of Passage Bio Inc, joining the firm since 2022.
What is the price performance of PASG stock?
The current price of PASG is $8.25, it has increased 2.29% in the last trading day.
What are the primary business themes or industries for Passage Bio Inc?
Passage Bio Inc belongs to Biotechnology industry and the sector is Health Care
What is Passage Bio Inc market cap?
Passage Bio Inc's current market cap is $26.2M
Is Passage Bio Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Passage Bio Inc, including 4 strong buy, 6 buy, 1 hold, 0 sell, and 4 strong sell
